who's who

3 Houston innovators to know this week

This week's roundup of Houston innovators includes Carolyn Rodz of Hello Alice, Kimon Angelides of FemTec Health, and Lara Cottingham of Greentown Labs. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from health tech to clean energy — recently making headlines in Houston innovation.

Carolyn Rodz, CEO and founder of Hello Alice

Carolyn Rodz joins the Houston Innovators Podcast this week. Photo courtesy of Hello Alice

Hello Alice exists to serve small business founders through their entrepreneurial journeys — that's why Carolyn Rodz founded the company — and SMBs needed support more than ever last year.

As challenging as the pandemic was for Hello Alice, it was validating too. Rodz says the company had a 700 percent increase in revenue and an 1,100 percent acquisition growth.

"We'd never operated in a downcycle, but what we learned through that process was that we're a really valuable resource for business owners when times are great, but we're also a really valuable resource for them when times are tough," she says on this week's episode of the Houston Innovators Podcast. Click here to read more and stream the episode.

Kimon Angelides, founder, chairman, and interim CEO of FemTec Health,

Dr. Kimon Angelides is also the founder of Houston health tech startups Livongo Health and Vivante Health. Photo via LinkedIn

Kimon Angelides, who has founded a handful of Houston health tech startups, has announced his latest venture launched FemTec Health, a tech-enabled women's health sciences and beauty company focused on transforming the total healthcare experience for women. The company is emerging from stealth mode this week with already 10 million members, two clinical trials in progress, $38 million in funding, and a team of over 150.

"Our platform can be implemented across all areas including specialty care, wellness and prevention, reproductive care, sexual wellness, mental health, chronic care, and beyond," Angelides says in the release. "It is driven by state-of-the-art genomics and digital technologies that empower women to take control of their health at every stage of their life journey, based on their individual health profiles."

FemTec Health's business and growth model is to expand via acquisitions — and the company has several under its belt already, including beauty subscription box Birchbox, universal beauty store Mira Beauty, and beauty industry social marketing platform Liquid Grids, which has over 1.5 million members, according to the release. Click here to read more.

Lara Cottingham, chief of staff for Greentown Labs

As of this week, Lara Cottingham is the chief of staff at Greentown Labs. Photo via LinkedIn

Lara Cottingham is the new chief of staff for Greentown Labs, a Boston-area company that opened in Houston earlier this year. Cottingham previously served as the city of Houston's chief sustainability officer and the chief of staff for the city's Administration and Regulatory Affairs Department for the past seven years. In her new role, Cottingham will oversee the day-to-day operations and communications for Greentown's CEO Emily Reichert, along with key stakeholder engagements and strategic initiatives for the incubator.

"In working with Mayor Turner and Climate Mayors across the U.S., I saw how important partnerships are to helping cities decarbonize," says Cottingham in the release. "There is no better partner or place for climate action at work than Greentown Labs. Greentown is 100 percent committed to attracting and nurturing the energy companies of the future and making Houston the energy transition capital of the world. I'm excited to join the team and see how climatetech can help cities reach their climate goals." Click here to read more.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted